{"disease": "glioblastoma", "drug": "ABT-414", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification [https://clinicaltrials.gov/study/NCT02573324]", "UNITE Study: Understanding New Interventions With GBM ThErapy [https://clinicaltrials.gov/study/NCT03419403]"]}}
{"disease": "glioblastoma", "drug": "AEE788", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) [https://clinicaltrials.gov/study/NCT00116376]", "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme [https://clinicaltrials.gov/study/NCT00107237]"]}}
{"disease": "glioblastoma", "drug": "Acalabrutinib", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) [https://clinicaltrials.gov/study/NCT02586857]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling. [https://pubmed.ncbi.nlm.nih.gov/34577576/]"]}}
{"disease": "glioblastoma", "drug": "Afatinib", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Pilot Trial for Treatment of Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT05432518]", "Safety Study of Afatinib for Brain Cancer [https://clinicaltrials.gov/study/NCT02423525]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["PUMA mediated afatinib-induced apoptosis in glioma cells. [https://pubmed.ncbi.nlm.nih.gov/41078912/]", "Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. [https://pubmed.ncbi.nlm.nih.gov/31215502/]"]}}
{"disease": "glioblastoma", "drug": "Apatinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors [https://clinicaltrials.gov/study/NCT03660761]", "Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma [https://clinicaltrials.gov/study/NCT03567135]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis. [https://pubmed.ncbi.nlm.nih.gov/34635636/]"]}}
{"disease": "glioblastoma", "drug": "BAY1436032", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "BEZ235", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 [https://clinicaltrials.gov/study/NCT02430363]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. [https://pubmed.ncbi.nlm.nih.gov/26188279/]", "Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/24366691/]", "Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. [https://pubmed.ncbi.nlm.nih.gov/22989521/]"]}}
{"disease": "glioblastoma", "drug": "Bevacizumab", "Q1": {"selection": "FDA-Approved to glioblastoma", "clinicaltrial_references": ["Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas [https://clinicaltrials.gov/study/NCT03532295]", "VB-111 in Surgically Accessible Recurrent/Progressive GBM [https://clinicaltrials.gov/study/NCT04406272]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model. [https://pubmed.ncbi.nlm.nih.gov/36703992/]", "A promise of nose to brain delivery of bevacizumab intranasal sol-gel formulation substantiated in rat C6 glioma model. [https://pubmed.ncbi.nlm.nih.gov/39417842/]"]}}
{"disease": "glioblastoma", "drug": "Bleomycin", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme [https://clinicaltrials.gov/study/NCT00006916]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Human brain glioblastoma cells do not induce but do respond to the bleomycin-induced bystander response from lung adenocarcinoma cells. [https://pubmed.ncbi.nlm.nih.gov/23906726/]", "Bleomycin delivery into cancer cells in vitro with ultrasound and SonoVue® or BR14® microbubbles. [https://pubmed.ncbi.nlm.nih.gov/23336182/]", "Chemosensitivity of glioma cells in vitro: a meta analysis. [https://pubmed.ncbi.nlm.nih.gov/10480340/]"]}}
{"disease": "glioblastoma", "drug": "Bortezomib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) [https://clinicaltrials.gov/study/NCT03643549]", "Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma [https://clinicaltrials.gov/study/NCT00998010]"]}}
{"disease": "glioblastoma", "drug": "Brentuximab vedotin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "CC-223", "Q1": {"selection": "No", "clinicaltrial_references": ["Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma [https://clinicaltrials.gov/study/NCT01177397]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Cabozantinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT05039281]", "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme [https://clinicaltrials.gov/study/NCT00704288]", "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma [https://clinicaltrials.gov/study/NCT00960492]", "Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse [https://clinicaltrials.gov/study/NCT01068782]"]}}
{"disease": "glioblastoma", "drug": "Carmustine", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) [https://clinicaltrials.gov/study/NCT05052957]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/39444362/]", "Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment. [https://pubmed.ncbi.nlm.nih.gov/36067850/]"]}}
{"disease": "glioblastoma", "drug": "Cenegermin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Cetuximab", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT02861898]", "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA [https://clinicaltrials.gov/study/NCT02800486]", "Cetuximab, Radiotherapy, and Temozolomide in treating primary Glioblastoma Multiforme [https://clinicaltrials.gov/study/NCT00311857]"]}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Exosome-mediated delivery platform of biomacromolecules into the brain: Cetuximab in combination with doxorubicin for glioblastoma therapy. [https://pubmed.ncbi.nlm.nih.gov/38815637/]", "AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy. [https://pubmed.ncbi.nlm.nih.gov/38428068/]", "Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: An (89)Zr-cetuximab immunoPET study. [https://pubmed.ncbi.nlm.nih.gov/36529256/]"]}}
{"disease": "glioblastoma", "drug": "Cyclophosphamide", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG [https://clinicaltrials.gov/study/NCT04049669]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. [https://pubmed.ncbi.nlm.nih.gov/28570014/]"]}}
{"disease": "glioblastoma", "drug": "Dacomitinib", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. [https://clinicaltrials.gov/study/NCT01520870]", "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT01112527]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma. [https://pubmed.ncbi.nlm.nih.gov/36991174/]", "A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors. [https://pubmed.ncbi.nlm.nih.gov/29574250/]", "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/25939761/]"]}}
{"disease": "glioblastoma", "drug": "Dactinomycin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Focal chemotherapy of brain tumours using semipermeable membranes. [https://pubmed.ncbi.nlm.nih.gov/69017/]"]}}
{"disease": "glioblastoma", "drug": "Dinutuximab", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors [https://clinicaltrials.gov/study/NCT04238819]"]}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. [https://pubmed.ncbi.nlm.nih.gov/34244307/]"]}}
{"disease": "glioblastoma", "drug": "Doxorubicin", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT05864534]", "Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma [https://clinicaltrials.gov/study/NCT06356883]", "Pegylated Liposomal Doxorubicine combined with prolonged Temozolomide and radiotherapy in newly diagnosed glioblastoma patients [https://clinicaltrials.gov/study/NCT00944801]"]}}
{"disease": "glioblastoma", "drug": "FT-2102", "Q1": {"selection": "Completed phase I with positive result (or FDA-Approved for other diseases)", "clinicaltrial_references": ["A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [https://clinicaltrials.gov/study/NCT03684811]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Formestane", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "GSK2636771", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Connexin 43 confers chemoresistance through activating PI3K. [https://pubmed.ncbi.nlm.nih.gov/35022385/]"]}}
{"disease": "glioblastoma", "drug": "Gefitinib", "Q1": {"selection": "No", "clinicaltrial_references": [{"title": "Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme", "NCTID": "NCT00052208", "drug_for_treatment": ["Gefitinib", "Radiation Therapy"], "indication": "Glioblastoma Multiforme", "result_summary_sentence": "The study aims to determine the maximum tolerated dose of gefitinib in combination with radiation therapy and assess overall survival and progression-free survival in patients with glioblastoma multiforme.", "phase": "Phase I/II", "risk_level": "High", "positive_or_negative": "Neutral", "population_summary": "Patients with histopathologically confirmed glioblastoma multiforme, supratentorial location, Zubrod performance status of 0-1, and estimated survival of at least 8 weeks.", "has_results": false, "sample_size": 60, "start_year": 2003, "this_year-start_year": 20, "complete_year": 2013}, {"title": "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma", "NCTID": "NCT00027625", "drug_for_treatment": ["Gefitinib", "Temozolomide"], "indication": "Malignant Primary Glioma", "result_summary_sentence": "The study aimed to evaluate the combination of Gefitinib and Temozolomide in treating patients with malignant primary glioma.", "phase": "Phase 1", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with malignant primary glioma, including glioblastoma, astrocytoma, oligodendroglioma, and gliosarcoma.", "has_results": false, "sample_size": 0, "start_year": 2002, "this_year-start_year": 21, "complete_year": 2007}, {"title": "Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research", "NCTID": "NCT00250887", "drug_for_treatment": ["Gefitinib"], "indication": "Recurrent Glioblastoma", "result_summary_sentence": "This study aimed to determine the effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment. The study is completed but has no posted results.", "phase": "Phase II", "risk_level": "Moderate", "positive_or_negative": "Unknown", "population_summary": "Patients with recurrent glioblastoma who have undergone standard treatment including surgery, radiation therapy, and at least one line of chemotherapy.", "has_results": false, "sample_size": 22, "start_year": 2005, "this_year-start_year": 2, "complete_year": 2007}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells. [https://pubmed.ncbi.nlm.nih.gov/33151388/]", "Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma. [https://pubmed.ncbi.nlm.nih.gov/31673738/]", "TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling. [https://pubmed.ncbi.nlm.nih.gov/31565489/]"]}}
{"disease": "glioblastoma", "drug": "IDH-C36", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "IDH1-IN-1", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "IDH305", "Q1": {"selection": "No", "clinicaltrial_references": ["A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations [https://clinicaltrials.gov/study/NCT02381886]", "Trial of IDH305 in IDH1 Mutant Grade II or III Glioma [https://clinicaltrials.gov/study/NCT02977689]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "INK128", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["A Phase I/II Study of MLN0128 (TAK-228) in Combination With Bevacizumab in Patients With Recurrent Glioblastoma or Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT02142803]", "Phase I Study of MLN0128 (TAK-228) in Combination With Bevacizumab in Patients With Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT02133183]"]}}
{"disease": "glioblastoma", "drug": "Interferon alfa-2b", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Ivosidenib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Lapatinib", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma [https://clinicaltrials.gov/study/NCT00350727]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models. [https://pubmed.ncbi.nlm.nih.gov/37733943/]", "Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy. [https://pubmed.ncbi.nlm.nih.gov/32517054/]", "Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. [https://pubmed.ncbi.nlm.nih.gov/29293494/]", "Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. [https://pubmed.ncbi.nlm.nih.gov/27489862/]"]}}
{"disease": "glioblastoma", "drug": "Lenalidomide", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I [https://clinicaltrials.gov/study/NCT00671801]", "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) [https://clinicaltrials.gov/study/NCT01183663]", "A Phase I Study of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors [https://clinicaltrials.gov/study/NCT00100880]"]}}
{"disease": "glioblastoma", "drug": "Lomustine", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma [https://clinicaltrials.gov/study/NCT06419946]"]}}
{"disease": "glioblastoma", "drug": "Mechlorethamine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Methotrexate", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme [https://clinicaltrials.gov/study/NCT00082797]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Uptake and Inhibition of P-Glycoprotein-Mediated Efflux Evaluation of Encapsulated Methotrexate Chitosan and Hypromellose Phthalate Nanoparticles for Potential Glioblastoma Treatment. [https://pubmed.ncbi.nlm.nih.gov/40006606/]", "Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1-T2* MRI contrast agent in U87MG cell detection. [https://pubmed.ncbi.nlm.nih.gov/38795276/]", "A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. [https://pubmed.ncbi.nlm.nih.gov/38607071/]", "Enhancing Methotrexate Delivery in the Brain by Mesoporous Silica Nanoparticles Functionalized with Cell-Penetrating Peptide using in Vivo and ex Vivo Monitoring. [https://pubmed.ncbi.nlm.nih.gov/36763486/]", "Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts. [https://pubmed.ncbi.nlm.nih.gov/34769063/]", "Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation. [https://pubmed.ncbi.nlm.nih.gov/32531377/]"]}}
{"disease": "glioblastoma", "drug": "Mogamulizumab", "Q1": {"selection": "No", "clinicaltrial_references": ["Expanded Access for KHK2455 [https://clinicaltrials.gov/study/NCT04321694]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Necitumumab", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Neratinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) [https://clinicaltrials.gov/study/NCT02977780]"]}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Nifurtimox", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Osimertinib", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT03732352]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Repurposing Osimertinib and Gedatolisib for Glioblastoma Treatment: Evidence of Synergistic Effects in an In Vitro Phenotypic Study. [https://pubmed.ncbi.nlm.nih.gov/39770465/]", "Efficacy of osimertinib against EGFRvIII+ glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/32547705/]"]}}
{"disease": "glioblastoma", "drug": "Paclitaxel", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "NCTID": "NCT02711137", "drug_for_treatment": ["INCB057643"], "indication": "Advanced Malignancies", "result_summary_sentence": "The study aims to evaluate the safety and tolerability of INCB057643 in subjects with advanced malignancies.", "phase": "Phase 1/2", "risk_level": "High", "positive_or_negative": "Positive", "population_summary": "Subjects with advanced malignancies including lymphoma, leukemia, myelodysplastic syndromes, multiple myeloma, myeloproliferative disorders, primary myelofibrosis, pancreatic neoplasms, colorectal neoplasms, non-small-cell lung carcinoma, prostatic neoplasms, breast neoplasms, ovarian neoplasms, glioblastoma, non-Hodgkin lymphoma, and diffuse large B-cell lymphoma.", "has_results": true, "sample_size": 100, "start_year": 2016, "this_year-start_year": 7, "complete_year": 2023}, "scoring": {"mechanism": {"score": 85, "explanation": "INCB057643 is a selective BET inhibitor, which targets bromodomain and extra-terminal domain proteins known to play a role in cancer cell proliferation and survival. BET inhibitors have shown promise in preclinical models of various cancers, supporting a strong mechanistic rationale."}, "clinical_evidence": {"score": 75, "explanation": "Early clinical signals from this Phase 1/2 study indicate positive results in terms of safety and tolerability, with some evidence of antitumor activity. However, detailed efficacy data is not yet fully available."}, "safety_predictability": {"score": 70, "explanation": "The safety profile of BET inhibitors is generally predictable, with known toxicities such as thrombocytopenia and gastrointestinal disturbances. The study reports manageable adverse events, supporting a moderate confidence in safety predictability."}, "trial_quality": {"score": 65, "explanation": "The trial design includes dose-escalation and dose-expansion phases, which are appropriate for early-phase studies. The endpoints focus on safety and tolerability, with secondary endpoints assessing preliminary efficacy."}, "result_status": {"score": 50, "category": "ongoing_in_reasonable_term", "explanation": "The study has been ongoing for 7 years, which is within a reasonable timeframe for Phase 1/2 trials. Positive preliminary results are available, but full efficacy data is still pending."}, "target_drug_importance": {"score": 90, "role": "major", "explanation": "INCB057643 is the primary experimental agent in this study, making its individual contribution central to the study outcomes."}, "overall_confidence": {"score": 75, "explanation": "Based on the strong mechanistic rationale, positive early clinical signals, and manageable safety profile, there is high confidence in the potential of INCB057643 for treating advanced malignancies. However, the lack of complete efficacy data tempers the overall confidence."}}, "nct_id": "NCT02711137"}, {"study_summary": {"title": "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)", "NCTID": "NCT02327078", "drug_for_treatment": ["Epacadostat", "Nivolumab"], "indication": "Advanced Cancers including Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Glioblastoma", "result_summary_sentence": "The study has available results indicating safety and tolerability, with some evidence of efficacy in select advanced cancers.", "phase": "Phase 1/2", "risk_level": "Moderate", "positive_or_negative": "Positive", "population_summary": "Patients with advanced cancers including colorectal, head and neck, lung, lymphoma, melanoma, ovarian, and glioblastoma.", "has_results": true, "sample_size": 601, "start_year": 2015, "this_year-start_year": 8, "complete_year": 2023}, "scoring": {"mechanism": {"score": 80, "explanation": "Epacadostat is an IDO1 inhibitor, which targets the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1. Nivolumab is a PD-1 inhibitor, which blocks the programmed death-1 pathway to enhance immune responses against tumors. The combination of these agents has a strong mechanistic rationale for treating various cancers."}, "clinical_evidence": {"score": 70, "explanation": "The study reports positive results in terms of safety and tolerability, with some evidence of efficacy in select advanced cancers. Detailed efficacy data is still pending, but early signals are promising."}, "safety_predictability": {"score": 65, "explanation": "The safety profiles of IDO1 and PD-1 inhibitors are generally predictable, with known toxicities such as immune-related adverse events. The study reports manageable adverse events, supporting moderate confidence in safety predictability."}, "trial_quality": {"score": 60, "explanation": "The trial design includes dose-escalation and dose-expansion phases, which are appropriate for early-phase studies. The endpoints focus on safety and tolerability, with secondary endpoints assessing preliminary efficacy."}, "result_status": {"score": 55, "category": "ongoing_in_reasonable_term", "explanation": "The study has been ongoing for 8 years, which is within a reasonable timeframe for Phase 1/2 trials. Positive preliminary results are available, but full efficacy data is still pending."}, "target_drug_importance": {"score": 85, "role": "major", "explanation": "Epacadostat and Nivolumab are the primary experimental agents in this study, making their individual contributions central to the study outcomes."}, "overall_confidence": {"score": 70, "explanation": "Based on the strong mechanistic rationale, positive early clinical signals, and manageable safety profile, there is high confidence in the potential of Epacadostat and Nivolumab for treating advanced cancers. However, the lack of complete efficacy data tempers the overall confidence."}}, "nct_id": "NCT02327078"}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Phytochemical combinations of lichen Evernia prunastri (L.) Ach. reduce drug resistance to temozolomide but not to paclitaxel in vitro. [https://pubmed.ncbi.nlm.nih.gov/41031155/]", "Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/40204132/]", "Chlorotoxin-functionalized mesoporous silica nanoparticles for pH-responsive paclitaxel delivery to Glioblastoma multiforme. [https://pubmed.ncbi.nlm.nih.gov/39758413/]", "Fabrication of Biomimetic Hybrid Liposomes via Microfluidic Technology: Homotypic Targeting and Antitumor Efficacy Studies in Glioma Cells. [https://pubmed.ncbi.nlm.nih.gov/39679250/]", "Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy. [https://pubmed.ncbi.nlm.nih.gov/39666995/]", "Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: An in vitro and in vivo study. [https://pubmed.ncbi.nlm.nih.gov/37926270/]", "Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. [https://pubmed.ncbi.nlm.nih.gov/37891669/]", "Super-small zwitterionic micelles enable the improvement of blood-brain barrier crossing for efficient orthotopic glioblastoma combinational therapy. [https://pubmed.ncbi.nlm.nih.gov/37839641/]", "Identification of a pH-Responsive Peptide-Paclitaxel Conjugate as a Novel Drug with Improved Therapeutic Potential. [https://pubmed.ncbi.nlm.nih.gov/37283311/]"]}}
{"disease": "glioblastoma", "drug": "Panitumumab", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["Panitumumab and Irinotecan for Malignant Gliomas [https://clinicaltrials.gov/study/NCT01017653]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme. [https://pubmed.ncbi.nlm.nih.gov/32606015/]"]}}
{"disease": "glioblastoma", "drug": "Pelitinib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Pictilisib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 [https://clinicaltrials.gov/study/NCT02430363]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["The effects of PI3K-mediated signalling on glioblastoma cell behaviour. [https://pubmed.ncbi.nlm.nih.gov/29184057/]"]}}
{"disease": "glioblastoma", "drug": "Plicamycin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Rituximab", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["(18)F]-Fludarabine for Hematological Malignancies. [https://pubmed.ncbi.nlm.nih.gov/31058154/]"]}}
{"disease": "glioblastoma", "drug": "Sodium phosphate P 3", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Temozolomide", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]", "A Phase II Randomized Trial of Veliparib (ABT-888) in Combination With Radiotherapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT02152982]", "Neoadjuvant Chemoradiation for Resectable Glioblastoma [https://clinicaltrials.gov/study/NCT04209790]"]}}
{"disease": "glioblastoma", "drug": "Thiotepa", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread [https://clinicaltrials.gov/study/NCT07193654]", "Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors [https://clinicaltrials.gov/study/NCT00179803]", "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer [https://clinicaltrials.gov/study/NCT00025558]"]}}
{"disease": "glioblastoma", "drug": "Trametinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Phase II Study of Dabrafenib and Trametinib in Children and Young Adults With BRAF V600-Mutant Recurrent or Refractory High-Grade Gliomas [https://clinicaltrials.gov/study/NCT03919071]", "Pediatric Long-Term Follow-up and Rollover Study [https://clinicaltrials.gov/study/NCT03975829]", "A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas [https://clinicaltrials.gov/study/NCT03593993]"]}}
{"disease": "glioblastoma", "drug": "Trifarotene", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Uracil mustard", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "glioblastoma", "drug": "Vinblastine", "Q1": {"selection": "No", "clinicaltrial_references": ["Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers [https://clinicaltrials.gov/study/NCT00498979]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. [https://pubmed.ncbi.nlm.nih.gov/18946672/]", "Chemosensitivity of glioma cells in vitro: a meta analysis. [https://pubmed.ncbi.nlm.nih.gov/10480340/]"]}}
{"disease": "glioblastoma", "drug": "Vincristine", "Q1": {"selection": "No", "clinicaltrial_references": ["Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion [https://clinicaltrials.gov/study/NCT06333899]", "Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma [https://clinicaltrials.gov/study/NCT03632135]", "Combination Chemotherapy in Treating Young Patients With Astrocytomas and Primitive Neuroectodermal Tumors [https://clinicaltrials.gov/study/NCT00002463]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Vincristine promotes differential levels of apoptosis, mitotic catastrophe, and senescence depending on the genetic background of glioblastoma cells. [https://pubmed.ncbi.nlm.nih.gov/36116745/]", "Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. [https://pubmed.ncbi.nlm.nih.gov/29861635/]", "Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. [https://pubmed.ncbi.nlm.nih.gov/26203691/]", "End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/25473893/]"]}}
{"disease": "glioblastoma", "drug": "Vorinostat", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT03426891]", "Vorinostat and Temozolomide in Treating Patients With Progressive or Relapsed Glioblastoma Multiforme, Anaplastic Astrocytoma, or Anaplastic Oligodendroglioma [https://clinicaltrials.gov/study/NCT00268385]", "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors [https://clinicaltrials.gov/study/NCT01076530]"]}}
